catechin has been researched along with Adenoma, Prostatic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korkmaz, M; Soya, E; Tepedelen, BE | 1 |
| Chen, J; Lei, Y; Zhou, J; Zhou, X | 1 |
| Gasiewicz, TA; Henry, EC; Moses, MA; Ricke, WA | 1 |
| Chen, J; Song, H | 1 |
| Altavilla, D; Arena, S; Bitto, A; Burnett, BP; Irrera, N; Magno, C; Minutoli, L; Polito, F; Rinaldi, M; Squadrito, F | 1 |
| Bettuzzi, S; Brausi, M; Castagnetti, G; Corti, A; Peracchia, G; Rizzi, F | 1 |
| Liao, S | 1 |
1 review(s) available for catechin and Adenoma, Prostatic
| Article | Year |
|---|---|
The medicinal action of androgens and green tea epigallocatechin gallate.
Topics: Androgens; Animals; Catechin; Complementary Therapies; Female; Humans; Male; Medicine, East Asian Traditional; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity; Tea | 2001 |
1 trial(s) available for catechin and Adenoma, Prostatic
| Article | Year |
|---|---|
Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
Topics: Administration, Oral; Aged; Catechin; Chemoprevention; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Quality of Life; Tea | 2006 |
5 other study(ies) available for catechin and Adenoma, Prostatic
| Article | Year |
|---|---|
Epigallocatechin-3-gallate reduces the proliferation of benign prostatic hyperplasia cells via regulation of focal adhesions.
Topics: Actin Cytoskeleton; Actins; Anticarcinogenic Agents; Catechin; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Focal Adhesions; Humans; Male; Prostatic Hyperplasia | 2017 |
Potential ameliorative effects of epigallocatechin‑3‑gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats.
Topics: Animals; Catechin; Collagen; Epithelial-Mesenchymal Transition; Fibrosis; Male; MicroRNAs; Oxidative Stress; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Androgen; Receptors, Estrogen; Smad3 Protein; Testosterone; Transforming Growth Factor beta1 | 2018 |
The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Catechin; Cell Movement; Cell Proliferation; Disease Progression; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Prostatic Hyperplasia; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Wound Healing; Xenograft Model Antitumor Assays | 2015 |
Protective potential of epigallocatechin-3-gallate against benign prostatic hyperplasia in metabolic syndrome rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Catechin; Cytokines; Disease Models, Animal; Male; Metabolic Syndrome; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Prostatic Hyperplasia; Rats, Sprague-Dawley; Somatomedins | 2016 |
Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; bcl-2-Associated X Protein; Caspase 9; Catechin; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Drug Combinations; Epidermal Growth Factor; Humans; Leukotriene B4; Lipoxygenase Inhibitors; Male; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Endothelial Growth Factor A | 2012 |